CD8+ T cell recognition of polymorphic wild-type sequence p53 65-73 peptides in squamous cell carcinoma of the head and neck

Cancer Immunology, Immunotherapy

Volumn 59, Issue 10, 2010, Pages 1561-1568

  Andrade Filho, Pedro A ^a   Ito, Daisuke ^b   Deleo, Albert B ^b   Ferris, Robert L ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Antigen presentation; Cytotoxic T lymphocytes; Tumor immunity

Indexed keywords

PROTEIN P53; PROTEIN P53[65-73]; PROTEIN P53[72P]; PROTEIN P53[72R]; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CODON; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEAD AND NECK CARCINOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNITY;

CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; PEPTIDES; POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955554458     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0886-1     Document Type: Article

References (31)

1. S Gnjatic Z Cai M Viguier S Chouaib JG Guillet J Choppin 1998 Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas J Immunol 160 1 328 333 1:CAS:528:DyaK1cXhtFWguw%3D%3D 9551988
2. M Theobald J Biggs D Dittmer AJ Levine LA Sherman 1995 Targeting p53 as a general tumor antigen Proc Natl Acad Sci USA 92 26 11993 11997 10.1073/pnas.92.26.11993 1:CAS:528:DyaK28Xhtlyrtw%3D%3D 8618830 (Pubitemid 26013997)
3. R Offringa MP Vierboom SH van der Burg L Erdile CJ Melief 2000 p53: a potential target antigen for immunotherapy of cancer Ann N Y Acad Sci 910 223 233 10.1111/j.1749-6632.2000.tb06711.x 1:CAS:528:DC%2BD3cXlsVOjt7g%3D 10911916 discussion 233-6
4. K Chikamatsu K Nakano WJ Storkus E Appella MT Lotze TL Whiteside, et al. 1999 Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells Clin Cancer Res 5 6 1281 1288 1:CAS:528:DyaK1MXkt1Oqurw%3D 10389910
5. J Hald N Rasmussen MH Claesson 1995 Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck Cancer Immunol Immunother 41 4 243 250 10.1007/BF01516999 1:STN:280: DyaK28%2FpsFOgug%3D%3D 7489567
6. M Ropke M Regner MH Claesson 1995 T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors Scand J Immunol 42 1 98 103 10.1111/j.1365-3083.1995.tb03631.x 1:CAS:528:DyaK2MXotFOjsLo%3D 7543215
7. AM Barfoed TR Petersen AF Kirkin P Thor Straten MH Claesson J Zeuthen 2000 Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein Scand J Immunol 51 2 128 133 10.1046/j.1365-3083.2000.00668.x 1:CAS:528:DC%2BD3cXhtlGnur0%3D 10652158 (Pubitemid 30095758)
8. TM McCarty Z Yu X Liu DJ Diamond JD Ellenhorn 1998 An HLA-restricted, p53 specific immune response from HLA transgenic p53 knockout mice Ann Surg Oncol 5 1 93 99 10.1007/BF02303770 1:STN:280:DyaK1c7osFCjsA%3D%3D 9524714 (Pubitemid 28328064)
9. HW Nijman SH Van der Burg MP Vierboom JG Houbiers WM Kast CJ Melief 1994 p53, a potential target for tumor-directed T cells Immunol Lett 40 2 171 178 10.1016/0165-2478(94)90189-9 1:CAS:528:DyaK2cXltlWrtLw%3D 8088874
10. M Theobald J Biggs J Hernandez J Lustgarten C Labadie LA Sherman 1997 Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes J Exp Med 185 5 833 841 10.1084/jem.185.5.833 1:CAS:528:DyaK2sXhsFKgs7o%3D 9120389 (Pubitemid 27119867)
11. TR Petersen S Buus S Brunak MH Nissen LA Sherman MH Claesson 2001 Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity Scand J Immunol 53 4 357 364 10.1046/j.1365-3083.2001.00887.x 1:CAS:528:DC%2BD3MXjtFWhtr0%3D 11285115 (Pubitemid 32275692)
12. TK Hoffmann DJ Loftus K Nakano MJ Maeurer K Chikamatsu E Appella, et al. 2002 The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope J Immunol 168 3 1338 1347 1:CAS:528:DC%2BD38XpsFeksQ%3D%3D 11801674
13. R Schneider-Stock C Mawrin C Motsch C Boltze B Peters R Hartig, et al. 2004 Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer Am J Pathol 164 4 1233 1241 1:CAS:528:DC%2BD2cXjsFemurs%3D 15039212
14. VL Buchman PM Chumakov NN Ninkina OP Samarina GP Georgiev 1988 A variation in the structure of the protein-coding region of the human p53 gene Gene 70 2 245 252 10.1016/0378-1119(88)90196-5 1:STN:280:DyaL1M7gvVSjug%3D%3D 2905688
15. CJ Lin JR Grandis TE Carey SM Gollin TL Whiteside WM Koch, et al. 2007 Head and neck squamous cell carcinoma cell lines: established models and rationale for selection Head Neck 29 2 163 188 10.1002/hed.20478 17312569 (Pubitemid 46167784)
16. DS Heo C Snyderman SM Gollin S Pan E Walker R Deka, et al. 1989 Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines Cancer Res 49 18 5167 5175 1:STN:280:DyaL1MzlsVaqtw%3D%3D 2766286
17. RL Ferris I Martinez N Sirianni J Wang A Lopez-Albaitero SM Gollin, et al. 2005 Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis Eur J Cancer 41 5 807 815 10.1016/j.ejca.2004.11.023 1:CAS:528:DC%2BD2MXitF2isbo%3D 15763658 (Pubitemid 40342563)
18. V Balz K Scheckenbach K Gotte U Bockmuhl I Petersen H Bier 2003 Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens Cancer Res 63 6 1188 1191 1:CAS:528:DC%2BD3sXit1Sgt7k%3D 12649174
19. N Sirianni PK Ha M Oelke J Califano W Gooding W Westra, et al. 2004 Effect of human papillomavirus-16 infection on CD8+ T cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck Clin Cancer Res 10 20 6929 6937 10.1158/1078-0432.CCR-04- 0672 1:CAS:528:DC%2BD2cXpslGltbg%3D 15501971 (Pubitemid 39383043)
20. R Birgander A Sjalander A Rannug AK Alexandrie MI Sundberg J Seidegard, et al. 1995 p53 polymorphisms and haplotypes in lung cancer Carcinogenesis 16 9 2233 2236 10.1093/carcin/16.9.2233 1:CAS:528:DyaK2MXot1ansLY%3D 7554081
21. RD Salter P Cresswell 1986 Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid EMBO J 5 5 943 949 1:CAS:528: DyaL28Xkt1altLk%3D 3522223
22. P Parham CJ Barnstable WF Bodmer 1979 Use of a monoclonal antibody (W6/32) in structural studies of HLA-A, B, C, antigens J Immunol 123 1 342 349 1:CAS:528:DyaE1MXkvV2gsbw%3D 87477
23. P Parham WF Bodmer 1978 Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2 Nature 276 5686 397 399 10.1038/276397a0 1:CAS:528:DyaE1MXhs1Kgurs%3D 714164
24. H Rammensee J Bachmann NP Emmerich OA Bachor S Stevanovic 1999 SYFPEITHI: database for MHC ligands and peptide motifs Immunogenetics 50 3-4 213 219 10.1007/s002510050595 1:CAS:528:DyaK1MXntlalsbs%3D 10602881
25. PA Filho A Lopez-Albaitero L Xi W Gooding T Godfrey RL Ferris 2009 Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer Int J Cancer 125 8 1912 1920 10.1002/ijc.24590 1:CAS:528:DC%2BD1MXhtVGisr%2FJ 19610063
26. TN Bullock DW Mullins TA Colella VH Engelhard 2001 Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice J Immunol 167 10 5824 5831 1:CAS:528:DC%2BD3MXotlamur4%3D 11698456
27. S Cairey-Remonnay O Humbey C Mougin MP Algros F Mauny J Kanitakis, et al. 2002 TP53 polymorphism of exon 4 at codon 72 in cutaneous squamous cell carcinoma and benign epithelial lesions of renal transplant recipients and immunocompetent individuals: lack of correlation with human papillomavirus status J Invest Dermatol 118 6 1026 1031 10.1046/j.1523-1747.2002.01787.x 1:CAS:528:DC%2BD38XlsV2rsL8%3D 12060398 (Pubitemid 34639182)
28. AN Rosenthal A Ryan RM Al-Jehani A Storey CA Harwood IJ Jacobs 1998 p53 codon 72 polymorphism and risk of cervical cancer in UK Lancet 352 9131 871 872 10.1016/S0140-6736(98)07357-7 1:CAS:528:DyaK1cXmtlOlsbY%3D 9742979 (Pubitemid 28416721)
29. H Shen Y Zheng EM Sturgis MR Spitz Q Wei 2002 P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study Cancer Lett 183 2 123 130 10.1016/S0304-3835(02)00117-9 1:CAS:528: DC%2BD38XksValsLg%3D 12065086 (Pubitemid 34628415)
30. G Sourvinos E Rizos DA Spandidos 2001 p53 codon 72 polymorphism is linked to the development and not the progression of benign and malignant laryngeal tumours Oral Oncol 37 7 572 578 10.1016/S1368-8375(00)00139-1 1:CAS:528:DC%2BD3MXmvVyrsbg%3D 11564578 (Pubitemid 32889619)
31. AE Albers RL Ferris GG Kim K Chikamatsu AB De Leo TL Whiteside 2005 Immune responses to p53 in patients with cancer: enrichment in tetramer +p53 peptide-specific T cells and regulatory T cells at tumor sites Cancer Immunol Immunother 54 11 1072 1081 10.1007/s00262-005-0670-9 1:CAS:528: DC%2BD2MXhtVClt7%2FJ 15959774 (Pubitemid 41396812)